PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Catalent completes cell therapy manufacturing facilities in Belgium

The facility represents one of the largest commercial-scale operations in the world.

Catalent – a company aiming to boost the supply of better patient treatments – has announced the opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell Therapy in Belgium.

The new facility becomes one of the largest of its type in the world, with 60,000 square feet of cell therapy manufacturing space along with suites designed to support cell therapy manufacturing through to late-stage clinical and commercial-scale supply.

It has also been designed to be both Europe, the Middle East and Africa and US Food and Drug Administration (FDA) compliant, with grade B and C suites to accommodate bioreactor-scale cell therapy manufacturing as well as on-site quality control (QC) laboratories.

The building is the latest addition to Catalent’s existing Gosselies campus, which already includes a 67,000-square-foot clinical manufacturing facility specialising in advanced clinical and commercial supply solutions.

The Gosselies campus also includes separate plasmid DNA development and manufacturing units. The clinical-scale facility, at 17,000 square feet, includes R&D and process development labs.

Meanwhile, the company’s cell therapy portfolio currently includes several cell types, including CAR-Ts, T-cell receptors, tumor-infiltrating lymphocyte cells, natural killer cells, induced pluripotent stem cells (iPSC) and mesenchymal stem cells.

Manja Boerman, Catalent’s President, reflected: “Catalent enables fully integrated cell therapy services, from our iPSC expertise in Düsseldorf, Germany, to process and analytical development in Gosselies, to clinical and commercial manufacturing in Princeton, New Jersey.”

“Together with our integrated plasmid DNA and viral vector services, the Catalent Cell & Gene Therapy network provides end-to-end services for development, scale up, and commercial launch of advanced therapies.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026